KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Palvella Therapeutics (PVLA) Accumulated Depreciation & Amortization (2016 - 2023)

Palvella Therapeutics has reported Accumulated Depreciation & Amortization over the past 10 years, most recently at $9.6 million for Q4 2022.

  • Quarterly Accumulated Depreciation & Amortization rose 25.01% to $9.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $9.6 million through Dec 2022, up 25.01% year-over-year, with the annual reading at $9.6 million for FY2022, 25.01% up from the prior year.
  • Accumulated Depreciation & Amortization was $9.6 million for Q4 2022 at Palvella Therapeutics, up from $8.3 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $9.6 million in Q4 2022 and troughed at $3.2 million in Q2 2018.
  • The 5-year median for Accumulated Depreciation & Amortization is $4.5 million (2020), against an average of $5.4 million.
  • Year-over-year, Accumulated Depreciation & Amortization rose 2.18% in 2019 and then skyrocketed 68.16% in 2021.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $3.4 million in 2018, then grew by 5.97% to $3.6 million in 2019, then skyrocketed by 63.02% to $5.8 million in 2020, then skyrocketed by 32.71% to $7.7 million in 2021, then increased by 25.01% to $9.6 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Accumulated Depreciation & Amortization are $9.6 million (Q4 2022), $8.3 million (Q3 2022), and $8.2 million (Q2 2022).